Role of Inflammatory Markers in Sepsis

N/ACompletedNCT06111963

National Cancer Institute, Egypt60 enrolled

Overview

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diagnostic

Interventions

Serology testsDIAGNOSTIC_TEST

CD4, CD25, IL17

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis Exclusion Criteria: * Refusal of patient or patient guardian to participate. * Intraoperative massive blood loss and massive blood transfusion * Patients with impaired preoperative kidney or liver function tests

Locations (1)

Walaa Y Elsabeeny

Cairo, Egypt

Outcomes

Primary Outcomes

To evaluate the expression CD4

Serology

Time frame: 7 days

To evaluate the expression CD25

Serology

Time frame: 7 days

To evaluate the expression IL17

Serology

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.